跳至主要内容
临床试验/CTRI/2025/10/095986
CTRI/2025/10/095986尚未招募不适用

Prevalence And Determinants Of Metabolic Associated Fatty Liver Disease (MAFLD) Among People Residing In Urban And Rural Areas Of Belagavi-Community Based Comparitive Study

Dr. AMRUTHA K1 个研究点 分布在 1 个国家目标入组 402 人开始时间: 2025年10月27日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
402
试验地点
1
主要终点
Primary objective: To evaluate the prevalence and determinants of Metabolic Associated Fatty Liver Disease (MAFLD) among people residing in urban and rural areas

研究概览

简要总结

India, with its rapidly developing economy and changing lifestyle, is witnessing a surge in non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD encompasses a spectrum of liver damage, from simple steatosis to cirrhosis and hepatocellular carcinoma, often associated with metabolic syndrome, diabetes, and dyslipidemia. Globally, NAFLD affects approximately 25% of the population, with India’s prevalence ranging from 6.7% to 55.1%. Urban areas show a higher prevalence (40.0%) compared to rural areas (29.2%). MAFLD’s new diagnostic criteria emphasize metabolic disorders, allowing for diagnosis regardless of alcohol consumption or co-existing liver diseases. While liver biopsy is the gold standard for diagnosis, non-invasive tools like vibration-controlled transient elastography (VCTE) are increasingly used to assess liver fibrosis and steatosis. As lifestyle and health factors evolve, MAFLD is projected to become the leading cause of chronic liver disease globally.

This study aims to assess the prevalence and determinants of MAFLD among adults in urban and rural Belagavi, informing public health research and prevention strategies.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Age more than 18 years and less than 65 years, residing in the same area for more than 1 year.

排除标准

  • Patients with history of alcohol intake more than 30 grams/ day in males and more than 20 grams/day in females.
  • Patients with history of jaundice or HBsAg positive and Hepatitis “C” positive.
  • Patients with history of following drug intake steroids, synthetic oestrogens, heparin, calcium channel blockers, amiodarone, valproic acid, arsenic, mercury, homeopathic drugs, ayurvedic drugs, antiviral agents.
  • Patients having autoimmune hepatitis.
  • History of drug abuse, opium, and nicotine.
  • Patients of Coronary artery disease.

结局指标

主要结局

Primary objective: To evaluate the prevalence and determinants of Metabolic Associated Fatty Liver Disease (MAFLD) among people residing in urban and rural areas

时间窗: 50 weeks

次要结局

  • Secondary objective: To assess the knowledge, awareness and attitude regarding Metabolic Associated Fatty Liver Disease (MAFLD) among people residing in urban and rural areas(50 weeks)

研究者

发起方
Dr. AMRUTHA K
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Amrutha K

Jawaharlal Nehru Medical College, Belagavi.

研究点 (1)

Loading locations...

相似试验